alexa Phototherapy And Excimer Laser Treatment For Vitiligo
ISSN: 2376-0427

Dermatology and Dermatologic Diseases
Open Access

Like us on:

Previously: Journal of Pigmentary Disorders

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

VI Master Class on Vitiligo and Pigmentary Disorders and Innovative Therapy in Dermatology Symposium, Split, Croatia, May 1-3, 2015

Kre?imir Kostović
Conference Proceedings: Pigmentary Disorders 2015
DOI: 10.4172/2376-0427.S11-010
Abstract
Ultraviolet therapeutic options, both in the range of UVB and UVA, are first line modalities for vitiligo affecting more than 10?20% of the skin surface. PUVA (psoralen and UVA radiation), a standard treatment in the past, is done 2?3 times weekly. The most common complication with PUVA is overdosage and severe burning. Narrow-band ultraviolet (NB-UVB) light has a wavelength of 311 ? 2 nm. It has been claimed as the UV treatment of choice for vitiligo. The efficacy of NB-UVB is comparable to that of PUVA, with the some advantages, such as the absence of psoralen side effects and reduced cumulative radiation dose and photocarcinogenesis. Furthermore, it can be safely used in children and in pregnant women. Sessions are repeated two or three times a week for a maximum period of 6?18 months. The best results are achieved on the face, followed by the trunk and limbs. The poorest outcomes have been noted for lesions on the hands and feet. The 308-nm excimer laser emits a monochromatic light of 308 nm and produces faster repigmentation rates than any other medical method so far reported. It permits the selective treatment of only lesional skin and ensures no unnecessary treatment of healthy skin. Thus, the patient receives less radiation.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords